Introduction of a mutation into the SapI site in RNase A cDNA.
Site-directed mutagenesis was performed to introduce a mutation into the SapI site in the RNase A cDNA clone. For mutagenesis, the following PCR reagents were mixed and water was added to a total volume of 50 μl: 3 μl of pRNase (4 μg/ml), 1 μl of forward and reverse primers (10 μM each), 5 μl of 10×PCR buffer for KOD-Plus-Neo, 5 μl of dNTPs (deoxyribonucleotides, 2 mM), 3 μl of MgSO 4 (25 mM), and 1 μl of KOD-Plus-Neo (1.0 U/μl; TOYOBO, Japan). The PCR was carried out at 94°C for 2 minutes, followed by 30 cycles of 98°C for 10 seconds, 50.5°C for 30 seconds, and 68°C for 3 minutes. Next, 50 μl of PCR product was incubated with 1 μl of DpnI (Takara Bio, Japan) at 37°C for 2 hours. The resulting product was transformed into E. coli HST08 Premium Competent Cells (Takara Bio, Japan) and seeded on Luria-Bertani (LB) agar plates containing 100 μg/ml of ampicillin. A single colony was picked and cultured in LB medium containing 100 μg/ml of ampicillin. The pRNase with a silent mutation in the SapI site was extracted using PureLink Quick Plasmid Miniprep Kit (Invitrogen, Carlsbad, CA, USA) and sequenced by a 3130xl Genetic Analyzer (Applied Biosystems, Carlsbad CA, USA).
Cloning of intein fusion RNase A (1-109) cDNA.
Primers were dissolved in Tris-EDTA (TE) at a stock concentration of 10 μM. The pRNase plasmid was diluted in TE at a stock concentration of 355 ng/μl. For the first PCR, the following reagents were mixed and water was added to a total volume of 50 μl: 1 μl of plasmid DNA (355 ng/μl), 1.25 μl of each primer (10 μM), 25 μl of 2×Gflex PCR Buffer (Mg 2+ , dNTP plus), and 1 μl of Tks Gflex DNA polymerase (1.25 U/μl, Takara Bio, Japan). The first PCR was performed using a PTC-200 cycler (MJ Research) at 94°C for 2 minutes, followed by 25 cycles of 98°C for 10 seconds, and 68°C for 15 seconds. Next, 1 μl of the first PCR product was mixed with the same PCR reagents except for the primers, and the second PCR was carried out at 94°C for 2 min, followed by 30 cycles of 98°C for 10 seconds, and 68°C for 15 seconds. The third and fourth PCRs were performed in the same way as the second, except that different primers was used (see Table 1 ). Each PCR product was checked by electrophoresis using a 1% agarose gel (Nippon gene) dissolved in Tris-Acetate-EDTA buffer. The fourth PCR product was purified by using UltraPure Phenol:Chloroform:Isoamyl Alcohol (25:24:1) (Invitrogen, Carlsbad, CA, USA) in accordance with the manufacturer's instructions. The purified fourth PCR product and pTXB1 plasmid (New England BioLabs, Massachusetts, USA) were digested by SapI and NdeI restriction enzymes at 37°C for 16 hours. The digested products were purified by gel electrophoresis and extracted by using a PureLink Quick Gl Extraction Kit (Invitrogen, Carlsbad, CA, U.S.A). The digested pTXB1 plasmid (25 fmol) and the digested PCR product (125 fmol) were mixed, TE was added to a total volume of 5 μl and then 5 μl of a DNA Ligation Kit was added (Takara Bio, Japan). The resulting construct was transformed into NEB turbo E. coli (New England BioLabs, Ipswich, MA, USA) and seeded on an LB agar plate containing 100 μg/ml of ampicillin. After overnight incubation at 37°C, single colonies were picked and the A (1-109) for protein ligation. pRNase-int was transformed into T7 Express lysY/Iq Competent E. coli (New England BioLabs, Ipswich, MA, USA) and then seeded on an LB agar plate containing 100 μg/ml of ampicillin. Single colonies were picked and the presence of the plasmid was checked by using colony direct PCR as described above. A colony containing the target plasmid was transferred to 2 ml of LB medium containing 100 μg/mL of ampicillin and incubated at 37°C overnight. The overnight culture was then transferred to 1 L of LB medium and incubated at 37°C with shaking until an OD 600 of approximately 0.5 was reached. Expression was induced by adding 0.6 mM isopropyl-β-D-thiogalactopyranoside (IPTG), and the cells were incubated for 9 hours at 25°C with shaking at 180 rpm. The cells were harvested by centrifugation at 6,000×g for 15 minutes at 4 °C, and then resuspended in 5 ml of lysis buffer (20 mM Tris-HCl pH7.4, 500 mM NaCl, 8 M Urea). The expressed protein was extracted by using an ultrasonic generator (UD-201, TOMY) on ice, and the supernatant was collected by centrifugation at 12,000×g for 30 minutes at 4°C. The supernatant was dialyzed against a dilution buffer (20 mM Tris-HCl pH7.4, 500 mM NaCl, 2 M Urea). A (1-109) .
Expression of intein-fused RNase

Purification of intein-fused RNase
Intein-fused RNase A (1-109) was purified by affinity chromatography using a HisPrep FF16/10 column (GE Healthcare Life Sciences) with a linear gradient of 0-250 mM imidazole in the presence of 20 mM Tris-HCl pH7.4, 500 mM NaCl, and 2 M Urea at a flow rate of 1 ml/min using an AKTA prime instrument (GE Healthcare Life Sciences). Elution of intein-fused RNase A was monitored at 280 nm and the protein was collected manually ( Figure S2 ). Figure S2 . Elution profile of intein fusion RNase A (1-109) using FF16/10 column with a linear gradient of 0-250 mM imidazole in the presence of 20 mM Tris-HCl pH7.4, 500 mM NaCl, and 2 M urea at a flow rate of 1 ml/min. Protein eluted between 120 and 160 min was collected.
